Rod and Cone Dystrophy is a progressive, inherited retinal condition that affects both the rod cells responsible for night and peripheral vision and the cone cells responsible for color and central vision. Patients typically first notice difficulty seeing in low light, followed by a gradual narrowing of the visual field and trouble distinguishing colors. India has become a preferred destination for **Stem cell therapy for Rod and Cone Dystrophy in Pakistan**, though it remains important to note that a definitive cure for this genetic condition is still a complex and ongoing pursuit within the medical field.
Progress in stem cell technology has introduced treatment approaches that hold meaningful relevance for patients affected by inherited photoreceptor disorders. In **Stem cell therapy for Rod and Cone Dystrophy**, a condition marked by the progressive loss of both rod and cone photoreceptor function, stem cell-based intervention is viewed as a supportive avenue rather than a guaranteed solution. This approach aims to support the surviving photoreceptor population and create conditions more favorable to slowing further retinal decline.
Mesenchymal stem cell injections via the Retro-bulbar route have proven to be a reliable option for patients with rod-cone disorders, typically requiring one or two sessions. This method has shown a favorable history in supporting the regenerative response of retinal cells affected by progressive photoreceptor degeneration. The regenerative capability of these cells extends to photoreceptor cells, retinal pigment epithelium, and macular cells, making the therapy broadly applicable across different stages of rod and cone dystrophy.
For patients from Pakistan managing this inherited condition, the Eye Stem Cell Center brings more than 12 years of focused experience with genetic retinal dystrophies. Patients are encouraged to connect with our team in India for a thorough, report-based evaluation of their specific case.
Eye Stem Cell Center is one of the most trusted providers of Stem cell therapy for Rod and Cone Dystrophy in Pakistan.

